University of Toledo, OH, USA.
Vasc Med. 2011 Oct;16(5):331-8. doi: 10.1177/1358863X11419998. Epub 2011 Sep 9.
Renal artery stenosis (RAS) is an important cause of renal failure; however, the factors associated with loss of kidney function in patients with RAS are poorly described, as are the predictors of an improvement in kidney function after stenting. One hundred patients at seven centers undergoing renal stenting were randomly assigned to an embolic protection device or double-blind use of a platelet glycoprotein IIb/IIIa inhibitor. The glomerular filtration rate (GFR) was measured using the creatinine-derived modified Modification of Diet in Renal Disease (MDRD) equation, cystatin C, and iohexol clearance. In univariate and multivariate models, baseline MDRD and cystatin C GFR were associated with congestive heart failure (CHF) (p = 0.01), lesion length (p = 0.01), and percent stenosis (-0.27, p = 0.01). In multivariate models, MDRD-estimated GFR 1 month after stenting was associated with bilateral stenosis (p < 0.05) and lesion length (p < 0.05), whereas with cystatin C the multivariate model included angiotensin receptor blocker (ARB) (p < 0.05) and minimal luminal diameter (MLD) (p < 0.05). The improvement in GFR from baseline to 1 month, measured as percent change, was related to baseline MDRD (p = 0.009) and cystatin C (p = 0.03) GFR. For MDRD GFR combined treatment with abciximab and Angioguard(®) embolic protection (p = 0.02) remained significant in multivariate analysis as did CHF, which was also significant with cystatin C (p = 0.05). In conclusion, CHF and lesion characteristics (MLD, percent stenosis and lesion length) are determinants of renal function in patients with RAS. In contrast, the acute improvement in renal function after revascularization is most strongly influenced by baseline GFR, and to a lesser degree CHF and combined procedural treatment with abciximab and embolic protection but not lesion characteristics. Clinical Trial Registration - URL:http://www.clinicaltrials.gov. Unique identifier: NCT00234585.
肾动脉狭窄 (RAS) 是肾功能衰竭的一个重要原因;然而,与 RAS 患者肾功能丧失相关的因素以及支架置入术后肾功能改善的预测因素描述得很差。在七个中心接受肾支架置入术的 100 名患者被随机分配到栓塞保护装置或血小板糖蛋白 IIb/IIIa 抑制剂的双盲使用。肾小球滤过率 (GFR) 使用肌酐衍生的改良肾脏病饮食修正公式 (MDRD)、胱抑素 C 和碘海醇清除率进行测量。在单变量和多变量模型中,基线 MDRD 和胱抑素 C GFR 与充血性心力衰竭 (CHF) (p = 0.01)、病变长度 (p = 0.01) 和狭窄程度 (-0.27,p = 0.01) 相关。在多变量模型中,支架置入术后 1 个月的 MDRD 估计 GFR 与双侧狭窄 (p < 0.05) 和病变长度 (p < 0.05) 相关,而胱抑素 C 的多变量模型包括血管紧张素受体阻滞剂 (ARB) (p < 0.05) 和最小管腔直径 (MLD) (p < 0.05)。从基线到 1 个月的 GFR 改善,以百分比变化表示,与基线 MDRD (p = 0.009) 和胱抑素 C (p = 0.03) GFR 相关。对于 MDRD GFR,联合使用阿昔单抗和 Angioguard®栓塞保护 (p = 0.02) 在多变量分析中仍然具有显著性,充血性心力衰竭也具有显著性,与胱抑素 C 相关 (p = 0.05)。总之,充血性心力衰竭和病变特征 (MLD、狭窄程度和病变长度) 是 RAS 患者肾功能的决定因素。相比之下,血管再通后肾功能的急性改善受基线 GFR 的影响最大,其次是充血性心力衰竭和联合使用阿昔单抗和栓塞保护的程序性治疗,但不受病变特征的影响。临床试验注册-网址:http://www.clinicaltrials.gov。独特标识符:NCT00234585。